Sign In
Buy RIGL
$30.30
+0.280 (+0.93%)
At Close: Jun 03, 2026
Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
08:05am, Wednesday, 08'th Oct 2025
Dose expansion phase will determine the recommended Phase 2 dose of R289 for patients with transfusion dependent R/R lower-risk MDS SOUTH SAN FRANCISCO, Calif. , Oct. 8, 2025 /PRNewswire/ -- Rigel Pha
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
08:05am, Friday, 03'rd Oct 2025
SOUTH SAN FRANCISCO, Calif. , Oct. 3, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. I
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
11:05am, Monday, 29'th Sep 2025
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Should Value Investors Buy Rigel Pharmaceuticals (RIGL) Stock?
10:41am, Monday, 29'th Sep 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Rigel (RIGL) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Friday, 26'th Sep 2025
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou
Rigel Pharmaceuticals: Strong Growth Trajectory And Commercial Expansion
10:53pm, Thursday, 25'th Sep 2025
Rigel Pharmaceuticals is a commercial-stage biotech growing revenue with three marketed drugs and a promising pipeline. RIGL's product sales grew 72% YoY in 1H FY2025, with diversification reducing re
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
12:31pm, Thursday, 25'th Sep 2025
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?
12:25pm, Thursday, 18'th Sep 2025
RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
10:51am, Thursday, 11'th Sep 2025
RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.
What Makes Rigel Pharmaceuticals (RIGL) a Strong Momentum Stock: Buy Now?
01:01pm, Tuesday, 09'th Sep 2025
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Rigel to Participate in Upcoming September Investor Conferences
08:05am, Tuesday, 26'th Aug 2025
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today an
Rigel Pharmaceuticals, Inc. (RIGL) Soars to 52-Week High, Time to Cash Out?
10:16am, Monday, 25'th Aug 2025
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Overlooked Stock: RIGL Nearly Doubles Stock in August
05:20pm, Friday, 15'th Aug 2025
Rigel Pharmaceuticals (RIGL) is up 88% in August and more than tripled its stock price over the last year. The staggering upside rally began with a massive earnings beat and raised guidance.
Rigel Pharmaceuticals: Q2 Earnings Fuel A Potential Breakout
11:58pm, Wednesday, 13'th Aug 2025
Rigel's Q2 results were outstanding, with revenue nearly doubling and net income surging, driven by strong commercial momentum for TAVALISSE, GAVRETO, and REZLIDHIA. Management raised 2025 guidance, e
Earnings Estimates Moving Higher for Rigel (RIGL): Time to Buy?
01:20pm, Friday, 08'th Aug 2025
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
